CA1341444C - Activateur tissulaire du plasminogene modifie - Google Patents

Activateur tissulaire du plasminogene modifie Download PDF

Info

Publication number: CA1341444C
Authority: CA; Canada
Prior art keywords: domain; region; fibrin; cells; kringle
Prior art date: 1986-01-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000528043A

Other languages

English (en)

Inventor

Margaret Y. Insley

Donald D. Rao

Eileen R. Mulvihill

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zymogenetics Inc

Original Assignee

Zymogenetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-01-24

Filing date

1987-01-23

Publication date

2003-10-21

1987-01-23 Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc

2003-10-21 Application granted granted Critical

2003-10-21 Publication of CA1341444C publication Critical patent/CA1341444C/fr

2020-10-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000373 Tissue Plasminogen Activator Proteins 0.000 title claims abstract description 9
102000003978 Tissue Plasminogen Activator Human genes 0.000 title claims description 8
229960000187 tissue plasminogen activator Drugs 0.000 title description 2
108050006955 Tissue-type plasminogen activator Proteins 0.000 claims abstract description 247
102100033571 Tissue-type plasminogen activator Human genes 0.000 claims abstract description 246
108090000623 proteins and genes Proteins 0.000 claims abstract description 76
102000009123 Fibrin Human genes 0.000 claims abstract description 73
108010073385 Fibrin Proteins 0.000 claims abstract description 73
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 73
229950003499 fibrin Drugs 0.000 claims abstract description 73
102000004169 proteins and genes Human genes 0.000 claims abstract description 59
230000027455 binding Effects 0.000 claims abstract description 48
238000000034 method Methods 0.000 claims abstract description 43
230000004071 biological effect Effects 0.000 claims abstract description 30
102000012479 Serine Proteases Human genes 0.000 claims abstract description 27
108010022999 Serine Proteases Proteins 0.000 claims abstract description 27
230000000694 effects Effects 0.000 claims abstract description 27
239000013604 expression vector Substances 0.000 claims abstract description 26
230000003197 catalytic effect Effects 0.000 claims abstract description 22
239000002773 nucleotide Substances 0.000 claims abstract description 21
125000003729 nucleotide group Chemical group 0.000 claims abstract description 21
230000014509 gene expression Effects 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 100
150000001413 amino acids Chemical group 0.000 claims description 35
239000013598 vector Substances 0.000 claims description 34
210000004962 mammalian cell Anatomy 0.000 claims description 19
230000001580 bacterial effect Effects 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
210000005253 yeast cell Anatomy 0.000 claims 2
239000002299 complementary DNA Substances 0.000 abstract description 39
230000006820 DNA synthesis Effects 0.000 abstract description 2
239000012634 fragment Substances 0.000 description 54
108020004414 DNA Proteins 0.000 description 45
239000013612 plasmid Substances 0.000 description 40
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
238000012217 deletion Methods 0.000 description 23
230000037430 deletion Effects 0.000 description 23
108091034117 Oligonucleotide Proteins 0.000 description 22
239000003102 growth factor Substances 0.000 description 19
241000588724 Escherichia coli Species 0.000 description 18
239000000872 buffer Substances 0.000 description 17
108091026890 Coding region Proteins 0.000 description 16
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 14
102000013566 Plasminogen Human genes 0.000 description 14
108010051456 Plasminogen Proteins 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
240000004808 Saccharomyces cerevisiae Species 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 11
239000000499 gel Substances 0.000 description 11
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
239000000203 mixture Substances 0.000 description 10
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 9
108010000521 Human Growth Hormone Proteins 0.000 description 9
239000002609 medium Substances 0.000 description 9
231100000350 mutagenesis Toxicity 0.000 description 9
238000002703 mutagenesis Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
102000002265 Human Growth Hormone Human genes 0.000 description 8
239000000854 Human Growth Hormone Substances 0.000 description 8
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 8
239000003527 fibrinolytic agent Substances 0.000 description 8
230000003480 fibrinolytic effect Effects 0.000 description 8
239000003550 marker Substances 0.000 description 8
244000005700 microbiome Species 0.000 description 8
229940012957 plasmin Drugs 0.000 description 8
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
108010039627 Aprotinin Proteins 0.000 description 7
108010017826 DNA Polymerase I Proteins 0.000 description 7
102000004594 DNA Polymerase I Human genes 0.000 description 7
229920002684 Sepharose Polymers 0.000 description 7
229960004405 aprotinin Drugs 0.000 description 7
238000003556 assay Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
241000894006 Bacteria Species 0.000 description 6
108010021466 Mutant Proteins Proteins 0.000 description 6
102000008300 Mutant Proteins Human genes 0.000 description 6
238000010276 construction Methods 0.000 description 6
230000009089 cytolysis Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000003362 replicative effect Effects 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
241000233866 Fungi Species 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 5
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
231100000219 mutagenic Toxicity 0.000 description 5
230000003505 mutagenic effect Effects 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
101100448340 Arabidopsis thaliana GG3 gene Proteins 0.000 description 4
108700024394 Exon Proteins 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000008272 agar Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000007858 starting material Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
230000014616 translation Effects 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
241000228212 Aspergillus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
102100037362 Fibronectin Human genes 0.000 description 3
108010067306 Fibronectins Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
102000001938 Plasminogen Activators Human genes 0.000 description 3
108010001014 Plasminogen Activators Proteins 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
230000003321 amplification Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000012160 loading buffer Substances 0.000 description 3
239000006166 lysate Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
229940079938 nitrocellulose Drugs 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
229940127126 plasminogen activator Drugs 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
101150019416 trpA gene Proteins 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
101150074155 DHFR gene Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
102000010911 Enzyme Precursors Human genes 0.000 description 2
108010062466 Enzyme Precursors Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
241001672648 Vieira Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
102000047823 human PLAT Human genes 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
239000000463 material Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
235000020046 sherry Nutrition 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
241000894007 species Species 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000012085 test solution Substances 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
238000001262 western blot Methods 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
241000351920 Aspergillus nidulans Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
241001465318 Aspergillus terreus Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
241000501458 Cultus Species 0.000 description 1
BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 1
JIVJQYNNAYFXDG-LKXGYXEUSA-N Cys-Thr-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JIVJQYNNAYFXDG-LKXGYXEUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
101100013965 Danio rerio gata3 gene Proteins 0.000 description 1
102100029211 E3 ubiquitin-protein ligase TTC3 Human genes 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
ZKJZBRHRWKLVSJ-ZDLURKLDSA-N Gly-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O ZKJZBRHRWKLVSJ-ZDLURKLDSA-N 0.000 description 1
VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000633723 Homo sapiens E3 ubiquitin-protein ligase TTC3 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
108010079364 N-glycylalanine Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102100032491 Serine protease 1 Human genes 0.000 description 1
101710151387 Serine protease 1 Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
VBPDMBAFBRDZSK-HOUAVDHOSA-N Thr-Asn-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VBPDMBAFBRDZSK-HOUAVDHOSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
238000000137 annealing Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000012514 protein characterization Methods 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
230000034005 thiol-disulfide exchange Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
229960000401 tranexamic acid Drugs 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA000528043A 1986-01-24 1987-01-23 Activateur tissulaire du plasminogene modifie Expired - Lifetime CA1341444C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82200586A	1986-01-24	1986-01-24
US06/822,005		1986-01-24

Publications (1)

Publication Number	Publication Date
CA1341444C true CA1341444C (fr)	2003-10-21

Family

ID=25234849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000528043A Expired - Lifetime CA1341444C (fr)	1986-01-24	1987-01-23	Activateur tissulaire du plasminogene modifie

Country Status (2)

Country	Link
JP (1)	JP2518832B2 (fr)
CA (1)	CA1341444C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0827751T3 (da) *	1996-09-06	2003-03-31	Chemo Sero Therapeut Res Inst	Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8508717D0 (en) *	1985-04-03	1985-05-09	Beecham Group Plc	Composition
GB8508972D0 (en) *	1985-04-04	1985-05-09	Beecham Group Plc	Compounds
NZ217331A (en) *	1985-08-26	1989-05-29	Lilly Co Eli	Tissue plasminogen activator derivatives and genetically engineered product
JPS63501841A (ja) *	1985-12-20	1988-07-28	ジ・アップジョン・カンパニ−	組織プラスミノ−ゲンアクチベ−タ−（ｔｐａ）同族体

1987
- 1987-01-23 CA CA000528043A patent/CA1341444C/fr not_active Expired - Lifetime
- 1987-01-24 JP JP62015053A patent/JP2518832B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2518832B2 (ja)	1996-07-31
JPS63133988A (ja)	1988-06-06

Legal Events

Date	Code	Title	Description
2020-12-23	MKEX	Expiry	Effective date: 20201021

Publication	Publication Date	Title
EP0092182B1 (fr)	1994-10-12	Préparation de polypeptides fonctionnelles d'urokinase humaine
EP0178105B1 (fr)	1997-04-02	Techniques d'ADN recombinant et produits ainsi obtenus
EP0231624B1 (fr)	1993-01-27	Analogues de l'activateur de plasminogène de tissu
JP2610783B2 (ja)	1997-05-14	ポリクリングルプラスミノーゲン活性化因子をコードする遺伝子およびそれを含有するベクター
US5200340A (en)	1993-04-06	Thrombin-activated tissue plasminogen activators
EP0234051B1 (fr)	1991-12-11	Mutants de l'activateur de plasminogène tissulaire; information recombinante génétique codant pour celui-ci et procédéde préparation de ces mutants, leur application et compositions pharmaceutiques
EP0292009A1 (fr)	1988-11-23	Protéines fibrinolytiques
US5504001A (en)	1996-04-02	Hybrid plasminogen activator
EP0293934B1 (fr)	1994-08-31	t-PA mutant avec remplacement de kringle
EP0277313B1 (fr)	1997-01-22	Activateur de plasminogène hybride
US5403734A (en)	1995-04-04	t-PA with growth factor domain substitutions
US5112755A (en)	1992-05-12	Preparation of functional human urokinase proteins
US5073494A (en)	1991-12-17	Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277
US5149533A (en)	1992-09-22	Modified t-PA with kringle-/replaced by another kringle
EP0424405A1 (fr)	1991-05-02	Variants d'activateurs de plasminogene et leurs procede de production.
EP0299706A2 (fr)	1989-01-18	Activateur du plasminogène non glycosyte, et sa méthode de fabrication
CA1341444C (fr)	2003-10-21	Activateur tissulaire du plasminogene modifie
US5486471A (en)	1996-01-23	Tissue plasminogen activator analogs having modified growth factor domains
US5409700A (en)	1995-04-25	Pharmaceutical compositions comprising modified and unmodified plasminogen activators
EP0316068A1 (fr)	1989-05-17	Activateur du plasminogène modifié de bas poids moléculaire et méthode pour sa préparation
US5580559A (en)	1996-12-03	Hybrid plasminogen activator
US5242819A (en)	1993-09-07	DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase
US5045315A (en)	1991-09-03	Process for treating thrombosis by administering poly-kringle plasminogen activator
GB2121050A (en)	1983-12-14	Preparation of functional human urokinase proteins
HK1005037B (en)	1998-12-18	Hybrid plasminogen activators